Differences in Aqueous Concentrations of Cytokines in Macular Edema Secondary to Branch and Central Retinal Vein Occlusion

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Feng, Jing ^a   Zhao, Tong ^a   Zhang, Yan ^a   Ma, Yan ^a   Jiang, Yanrong ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOKINE; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; SERUM AMYLOID A; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADULT; AQUEOUS HUMOR; ARTICLE; BRANCH RETINA VEIN OCCLUSION; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; MALE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION;

ADULT; AGED; AQUEOUS HUMOR; CYTOKINES; FEMALE; HUMANS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION;

EID: 84879832365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068149     Document Type: Article

References (34)

1. Klein R, Klein BE, Moss SE, Meuer SM, (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98: 133-141.
2. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, et al. (2009) Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 147: 298-306.
3. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, et al. (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117: 313-319.
4. Clarkson JG (1994) Central Vein Occlusion Study: photographic protocol and early natural history. Trans Am Ophthalmol Soc 92: 203-213; discussion 213-205.
5. Cugati S, Wang JJ, Rochtchina E, Mitchell P, (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124: 726-732.
6. Turello M, Pasca S, Daminato R, Dello Russo P, Giacomello R, et al. (2010) Retinal vein occlusion: evaluation of "classic" and "emerging" risk factors and treatment. J Thromb Thrombolysis 29: 459-464.
7. Channa R, Smith M, Campochiaro PA, (2011) Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol 5: 705-713.
8. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 115: 486-491.
9. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, et al. (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50: 1025-1032.
10. Kaneda S, Miyazaki D, Sasaki S, Yakura K, Terasaka Y, et al. (2011) Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci 52: 2982-2988.
11. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, et al. (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 22: 42-48.
12. Park CH, Jaffe GJ, Fekrat S, (2003) Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 136: 419-425.
13. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y, (2011) Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 55: 256-263.
14. Hayreh SS, (1983) Classification of central retinal vein occlusion. Ophthalmology 90: 458-474.
15. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 102: 1425-1433.
16. Stahl A, Struebin I, Hansen LL, Agostini HT, Feltgen N, (2010) Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. Eur J Ophthalmol 20: 180-185.
17. Nuti E, Traversi C, Marigliani D, Balestrazzi A, Alegente M, et al. (2011) Treatment of macular edema because of occlusive vasculitis with bevacizumab (avastin): efficacy of three consecutive monthly injections. Retina 31: 1863-1870.
18. Hung KH, Lee SM, Lee SY, Lee FL, Yang CS, (2010) Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. J Ocul Pharmacol Ther 26: 85-90.
19. Ding X, Li J, Hu X, Yu S, Pan J, et al. (2011) Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 31: 838-845.
20. Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, et al. (2011) Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 152: 686-694.
21. Lee WJ, Kang MH, Seong M, Cho HY, (2012) Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol 96: 1426-1430.
22. Uhlar CM, Whitehead AS, (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265: 501-523.
23. Urieli-Shoval S, Linke RP, Matzner Y, (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7: 64-69.
24. Upragarin N, Asten AJ, PC JT, WJ ML, Gruys E, (2005) Serum amyloid A production by chicken fibroblast-like synoviocytes. Vet Immunol Immunopathol 106: 39-51.
25. Ma Y, Tao Y, Lu Q, Jiang YR (2011) Intraocular expression of serum amyloid a and interleukin-6 in proliferative diabetic retinopathy. Am J Ophthalmol 152: 678-685 e672.
26. Jones LL, Vignali DA, (2011) Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunol Res 51: 5-14.
27. Tanaka T, Narazaki M, Kishimoto T, (2012) Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52: 199-219.
28. Holzinger C, Weissinger E, Zuckermann A, Imhof M, Kink F, et al. (1993) Effects of interleukin-1,-2,-4,-6, interferon-gamma and granulocyte/macrophage colony stimulating factor on human vascular endothelial cells. Immunol Lett 35: 109-117.
29. D'Amore PA, (1994) Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 35: 3974-3979.
30. Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L, (1990) Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 108: 869-872.
31. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW, (1996) Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122: 393-403.
32. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, et al. (2002) Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 120: 1644-1650.
33. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, et al. (2008) Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 16: 791-799.
34. Zittermann SI, Issekutz AC, (2006) Basic fibroblast growth factor (bFGF, FGF-2) potentiates leukocyte recruitment to inflammation by enhancing endothelial adhesion molecule expression. Am J Pathol 168: 835-846.